Zoladex in the treatment of premenopausal metastatic breast cancer patients.
In an open phase II, multicentre study with 118 pre- or perimenopausal women with histologically proven advanced breast cancer, Zoladex depot (3.6 mg) has been shown to produce an effective castration and response rates, which are comparable to those from oophorectomy.